What Arbutus Biopharma Corp's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 17 | 19 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 682,630 | 784,130 |
| Disposed | 9,563,938 | 9,563,938 |
| Net activity | −8,881,308 | −8,779,808 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director | Oct 01 | Disposition to Issuer · D | −8,967,383 | $5.00 | −$44.8M | 29,880,079 |
| Nguyen Tuan | Chief Financial Officer | Oct 01 | Disposition to Issuer · D | −48,081 | $5.00 | −$240K | 111,882 |
| Sawhney Roger | Director | Oct 01 | Disposition to Issuer · D | −17,142 | $5.00 | −$85.7K | 13,683 |
| Androski Lindsay | President and CEO | Oct 01 | Disposition to Issuer · D | −24,655 | $5.00 | −$123K | 47,682 |
| Beardsley Robert A | Director | Oct 01 | Disposition to Issuer · D | −17,948 | $5.00 | −$89.7K | 14,328 |
| Androski Lindsay | President and CEO | Sep 18 | Withheld — tax / exercise cost · F | −82,527 | $5.07 | −$418K | 72,337 |
| Androski Lindsay | President and CEO | Sep 18 | Exercise / conversion · M | +10,456 | $4.39 | +$45.9K | 154,864 |
| Androski Lindsay | President and CEO | Sep 18 | Exercise / conversion · M | +116,408 | $3.20 | +$373K | 144,408 |
| Sawhney Roger | Director | Sep 18 | Withheld — tax / exercise cost · F | −100,508 | $5.07 | −$510K | 30,825 |
| Sawhney Roger | Director | Sep 18 | Exercise / conversion · M | +78,800 | $4.24 | +$334K | 131,333 |
| Sawhney Roger | Director | Sep 18 | Exercise / conversion · M | +52,533 | $3.34 | +$175K | 52,533 |
| Nguyen Tuan | Chief Financial Officer | Sep 18 | Withheld — tax / exercise cost · F | −206,637 | $5.07 | −$1.05M | 159,963 |
| Nguyen Tuan | Chief Financial Officer | Sep 18 | Exercise / conversion · M | +27,475 | $4.39 | +$121K | 366,600 |
| Nguyen Tuan | Chief Financial Officer | Sep 18 | Exercise / conversion · M | +265,625 | $3.49 | +$927K | 339,125 |
| Beardsley Robert A | Director | Sep 18 | Withheld — tax / exercise cost · F | −99,057 | $5.07 | −$502K | 32,276 |
| Beardsley Robert A | Director | Sep 18 | Exercise / conversion · M | +78,800 | $4.24 | +$334K | 131,333 |
| Beardsley Robert A | Director | Sep 18 | Exercise / conversion · M | +52,533 | $3.20 | +$168K | 52,533 |
| Androski Lindsay | President and CEO | Feb 02 | Grant / award · A | +28,000 | — | — | 28,000 |
| Nguyen Tuan | Chief Financial Officer | Feb 02 | Grant / award · A | +73,500 | — | — | 73,500 |
| Hastings David C | Chief Financial Officer | Feb 14 | Grant / award · A | +90,100 | — | — | 249,824 |
Loading...
